{"id":67893,"date":"2026-06-10T15:05:57","date_gmt":"2026-06-10T07:05:57","guid":{"rendered":"https:\/\/flcube.com\/?p=67893"},"modified":"2026-06-10T15:05:58","modified_gmt":"2026-06-10T07:05:58","slug":"burning-rock-reports-q1-2026-revenue-of-16m-accelerates-strategic-shift-to-in-hospital-testing-with-49-revenue-share","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67893","title":{"rendered":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Burning Rock Biotech Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BNR:NASDAQ\">NASDAQ: BNR<\/a>) reported <strong>Q1 2026 financial results<\/strong> with total revenue of <strong>CNY 108 million (USD 16 million)<\/strong>, reflecting a <strong>3.4% sequential increase<\/strong> and continued execution of its strategic pivot toward <strong>in-hospital testing<\/strong> solutions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The revenue breakdown included <strong>CNY 52.76 million (USD 7.78 million) from in-hospital testing<\/strong>, representing <strong>49% of total revenue<\/strong>\u2014a significant increase from <strong>43% in Q1 2025<\/strong>\u2014and <strong>CNY 32.42 million (USD 4.78 million) from central laboratory testing<\/strong>. <strong>Kit sales<\/strong> maintained steady growth, driven by sustained clinical demand at the point of care, while <strong>pharmaceutical collaboration revenue<\/strong> reached <strong>CNY 22.76 million (USD 3.35 million)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-summary\" class=\"wp-block-heading\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>Q1 2025<\/th><th>Sequential Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>CNY 108M (USD 16M)<\/td><td>Not disclosed<\/td><td>+3.4%<\/td><\/tr><tr><td><strong>In-Hospital Testing<\/strong><\/td><td>CNY 52.76M (USD 7.78M)<\/td><td>43% of revenue<\/td><td>49% of revenue (+6pp)<\/td><\/tr><tr><td><strong>Central Lab Testing<\/strong><\/td><td>CNY 32.42M (USD 4.78M)<\/td><td>Not disclosed<\/td><td>Declining share<\/td><\/tr><tr><td><strong>Pharma Collaboration<\/strong><\/td><td>CNY 22.76M (USD 3.35M)<\/td><td>Not disclosed<\/td><td>Stable contribution<\/td><\/tr><tr><td><strong>Cash Position<\/strong><\/td><td>CNY 449M (USD 66.27M)<\/td><td>Not disclosed<\/td><td>Strong liquidity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-business-transformation\" class=\"wp-block-heading\">Strategic Business Transformation<\/h2>\n\n\n\n<h3 id=\"h-in-hospital-testing-focus\" class=\"wp-block-heading\">In-Hospital Testing Focus<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Mix Shift<\/strong>: In-hospital testing now represents nearly half of total revenue (49% vs. 43% YoY)<\/li>\n\n\n\n<li><strong>Compliance Alignment<\/strong>: Strategic positioning aligned with China&#8217;s healthcare regulatory compliance requirements<\/li>\n\n\n\n<li><strong>Point-of-Care Demand<\/strong>: Kit sales growth driven by sustained clinical need for rapid, on-site diagnostics<\/li>\n\n\n\n<li><strong>Operational Foundation<\/strong>: Infrastructure investments supporting scalable in-hospital deployment<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-pharmaceutical-partnerships\" class=\"wp-block-heading\">Global Pharmaceutical Partnerships<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Client Base<\/strong>: Preferred partner for <strong>150+ innovative pharmaceutical companies<\/strong> globally<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: <strong>15+ diagnostic collaboration projects<\/strong> currently under development<\/li>\n\n\n\n<li><strong>Regulatory Approvals<\/strong>: Product clearances across <strong>China, U.S., Europe, and Japan<\/strong><\/li>\n\n\n\n<li><strong>Dual Accreditation<\/strong>: <strong>CLIA and CAP-accredited laboratories<\/strong> in both China and the U.S.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-advantages-amp-market-position\" class=\"wp-block-heading\">Competitive Advantages &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Intellectual Property<\/strong>: Robust patent portfolio protecting core technologies and methodologies<\/li>\n\n\n\n<li><strong>Product Matrix<\/strong>: Mature diagnostic platform spanning multiple therapeutic areas and testing modalities<\/li>\n\n\n\n<li><strong>Project Experience<\/strong>: Extensive track record in complex pharmaceutical diagnostic development programs<\/li>\n\n\n\n<li><strong>Global Footprint<\/strong>: Multi-jurisdictional regulatory expertise enabling international market access<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-strength-amp-growth-strategy\" class=\"wp-block-heading\">Financial Strength &amp; Growth Strategy<\/h2>\n\n\n\n<h3 id=\"h-cash-position-amp-capital-allocation\" class=\"wp-block-heading\">Cash Position &amp; Capital Allocation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Liquidity<\/strong>: <strong>CNY 449 million (USD 66.27 million)<\/strong> in cash, cash equivalents, and restricted cash as of March 31, 2026<\/li>\n\n\n\n<li><strong>Strategic Investments<\/strong>:<\/li>\n\n\n\n<li>Kit regulatory submissions across global markets<\/li>\n\n\n\n<li>Cutting-edge technology R&amp;D initiatives<\/li>\n\n\n\n<li>Domestic and international market expansion<\/li>\n\n\n\n<li><strong>Compliance-Driven Growth<\/strong>: Positioned to capitalize on industry-wide regulatory compliance trends<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-opportunity-context\" class=\"wp-block-heading\">Market Opportunity Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese IVD Market<\/strong>: Projected to reach $15 billion by 2028, with in-hospital testing representing fastest-growing segment<\/li>\n\n\n\n<li><strong>Pharma Diagnostics<\/strong>: Companion diagnostic market growing at 18% CAGR globally<\/li>\n\n\n\n<li><strong>Regulatory Tailwinds<\/strong>: China&#8217;s healthcare compliance initiatives favoring established, accredited providers<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This quarterly performance demonstrates Burning Rock&#8217;s successful navigation of China&#8217;s evolving healthcare regulatory landscape while maintaining strong financial discipline and expanding its global pharmaceutical partnership footprint.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, market opportunities, regulatory developments, and strategic initiatives. Actual results may differ due to competitive pressures, regulatory changes, and macroeconomic factors affecting the healthcare sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/burning-rock-reports-first-quarter-2026-financial.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of burning-rock-reports-first-quarter-2026-financial.\"><\/object><a id=\"wp-block-file--media-18e20b31-aee3-4d8d-8f31-c7f000033f3c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/burning-rock-reports-first-quarter-2026-financial.pdf\">burning-rock-reports-first-quarter-2026-financial<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/burning-rock-reports-first-quarter-2026-financial.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-18e20b31-aee3-4d8d-8f31-c7f000033f3c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,1108,2823],"class_list":["post-67893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nasdaq-bnr","tag-roc-rock-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67893\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share\" \/>\n<meta property=\"og:description\" content=\"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67893\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T07:05:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T07:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share\",\"datePublished\":\"2026-06-10T07:05:57+00:00\",\"dateModified\":\"2026-06-10T07:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893\"},\"wordCount\":466,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1002.webp\",\"keywords\":[\"Finanical Reports\",\"NASDAQ: BNR\",\"Roc Rock Biotechnology\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67893#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67893\",\"name\":\"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1002.webp\",\"datePublished\":\"2026-06-10T07:05:57+00:00\",\"dateModified\":\"2026-06-10T07:05:58+00:00\",\"description\":\"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67893\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67893#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share - Insight, China&#039;s Pharmaceutical Industry","description":"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67893","og_locale":"en_US","og_type":"article","og_title":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share","og_description":"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.","og_url":"https:\/\/flcube.com\/?p=67893","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T07:05:57+00:00","article_modified_time":"2026-06-10T07:05:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67893#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67893"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share","datePublished":"2026-06-10T07:05:57+00:00","dateModified":"2026-06-10T07:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67893"},"wordCount":466,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","keywords":["Finanical Reports","NASDAQ: BNR","Roc Rock Biotechnology"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67893#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67893","url":"https:\/\/flcube.com\/?p=67893","name":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67893#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67893#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","datePublished":"2026-06-10T07:05:57+00:00","dateModified":"2026-06-10T07:05:58+00:00","description":"Burning Rock Biotech Corporation (NASDAQ: BNR) reported Q1 2026 financial results with total revenue of CNY 108 million (USD 16 million), reflecting a 3.4% sequential increase and continued execution of its strategic pivot toward in-hospital testing solutions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67893#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67893"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67893#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","width":1080,"height":608,"caption":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67893#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67893"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67893\/revisions"}],"predecessor-version":[{"id":67898,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67893\/revisions\/67898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67897"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}